Cephalosporin Drugs Market Size, Share, and Trends 2024 to 2033

Cephalosporin Drugs Market Size to Reach USD 26.18 Bn by 2033

The global cephalosporin drugs market size was valued at USD 19.46 billion in 2023 and is anticipated to reach around USD 26.18 billion by 2033, growing at a CAGR of 3.01% from 2024 to 2033. The rising prevalence of bacterial infections is observed to drive the growth of the market.

Cephalosporin Drugs Market Key Takeaways

• The North America cephalosporin drugs market accounted for USD 7.98 billion in 2023 and is estimated to attain around USD 10.73 billion by 2033.
• North America led the largest market share of 41% in 2023.
• Asia Pacific is expected to witness the fastest growth in the market during the forecast period.
• By generation, the second-generation segment dominated the market with the largest share in 2023.
• By generation, the third-generation segment is expected to grow significantly during the forecast period.
• By route of administration, the oral segment has held the largest market share of 57% in 2023.
• By route of administration, the injection segment is expected to grow significantly during the forecast period.
• By application, the skin infection segment held the largest share of the market in 2023.
• By application, the respiratory tract infection segment is expected to witness a significant rate of growth during the forecast period.

Cephalosporin Drugs Market Size in the U.S. 2024 to 2033

The U.S. cephalosporin drugs market size was estimated at USD 5.98 billion in 2023 and is predicted to be worth around USD 8.10 billion by 2033, at a CAGR of 3.08% from 2024 to 2033.

North America led the cephalosporin drugs market with the largest market share in 2023. The expansion of the market in the region is due to the rising prevalence of bacterial infections in the population are driving the demand for the cephalosporin drugs market. The region's high healthcare spending per capita and widespread access to health insurance coverage ensure broad access to prescription medications, including cephalosporin drugs, for patients in need. This favorable reimbursement environment encourages healthcare providers to prescribe cephalosporins as frontline treatments for bacterial infections.

North America is home to several leading pharmaceutical companies that specialize in the research, development, manufacturing, and marketing of cephalosporin drugs. These companies benefit from access to advanced research facilities, skilled workforce, and robust intellectual property protections, enabling them to innovate and commercialize new cephalosporin formulations.

Asia Pacific is expected to witness the fastest growth in the market during the forecast period. The growth of the market is owing to the increasing population of the region and the improving healthcare infrastructure. Countries in Asia Pacific experience a significant burden of bacterial infections, including respiratory tract infections, urinary tract infections, skin and soft tissue infections, and bloodstream infections. The region's large population, dense urban areas, and modern lifestyle factors contribute to the spread of infectious diseases, driving demand for cephalosporin drugs.

Cephalosporin Drugs Market Size in Asia Pacific 2023 to 2033

The Asia Pacific cephalosporin drugs market was calculated at USD 4.67 billion in 2023 and is expected to grow around USD 6.41 billion by 2033, rising at a CAGR of 3.21% from 2024 to 2033.

Cephalosporin Drugs Market Overview

The cephalosporin drugs market is the industry that deals with the production and distribution of therapeutics used in the treatment of bacterial infections. Cephalosporin can be administered orally or can be injected into a vein that depends on the type of infection. Some types of infections such as skin or tissue infections, urinary tract infections, ear infections, strep throat, pneumonia, meningitis, sinus infections, and gonorrhea are treated by cephalosporin antibiotics. The cephalosporin drugs market encompasses a diverse range of medications, including first-generation to fifth generation cephalosporins, each with varying spectra of activity, pharmacokinetic properties, and clinical indications. These drugs are available in various formulations, including oral tablets, capsules, injections, and intravenous (IV) infusions, providing flexibility in treatment options for healthcare providers

Cephalosporin Drugs Market Growth Factors

• The rising prevalence of the infectious diseases that driving the demand for the effective and preventionary drug treatment that drives the growth of the market.
• The rising number of bacterial infections including staph infections, strep throat, pneumonia, sinusitis, tonsillitis, and others are driving the growth of the cephalosporin drugs market.
• The rising investments in the research and development activities in the latest drug formulation and the rising demand for the antibiotics are driving the expansion of the market.
• The increasing healthcare infrastructure and the rising investment in the pharmaceutical industry are driving the research on innovation of the new drug development that also contributed to the expansion of the market.
• The increasing number of infectious diseases due to the rising urbanization and industrialization that affecting the environment by the increased level of carbon emission which is hazardous to the human health that causes the increased number of infectious diseases.

Cephalosporin Drugs Market Scope

Cephalosporin Drugs Market Dynamics

Driver: Improving healthcare infrastructure

The rising investments in healthcare infrastructure for the improvisation purpose and efforts by pharmaceutical companies for the development of drug formulations are driving the growth of the cephalosporin drugs market. Moreover, upgradation of healthcare facilities in economically developing countries results in better quality medical infrastructure. The increasing prevalence of bacterial infections has increased the demand for effective treatment medicine that drives the advancements in drug development for bacterial treatment medicines. The rising investments by the public and private sector in the development of healthcare facilities, especially in developing economies and the increasing awareness campaign for bacterial infections are also propelling the growth of the cephalosporin drugs market.

Restraint: Side effects of the drugs

The side effects associated with the cephalosporin drugs are generally observed to limit the growth of the cephalosporin drugs market. The antibiotic resistance causes severe form of allergies. Antimicrobial resistance (AMR) is a major concern in healthcare worldwide, posing a significant threat to the effectiveness of antibiotics, including cephalosporins. Overuse and misuse of antibiotics have led to the emergence of multidrug-resistant bacteria, reducing the efficacy of cephalosporin drugs in treating bacterial infections. As a result, healthcare providers face challenges in selecting appropriate antibiotic therapies, leading to a decline in the demand for cephalosporin drugs. Additionally, stringent regulatory requirements for antimicrobial stewardship programs and efforts to curb antibiotic overprescribing further constrain market growth for cephalosporins.

Opportunity: Advancements in drug formulation

The technological advancements in the pharmaceutical industry and the rising research and development activities for the upgradation of drug formulation processes is observed to open lucrative opportunities for the cephalosporin drugs market. Industry players are focused on such developments, especially for better efficiency and faster recovery time, which supports the expansion of the market. The advancements in the cephalosporin drugs such as third generation and forth generation cephalosporin drugs that used in enhance the resistance against the infectious diseases and broader spectrum of bacteria. The rising investments in the research and development activities by the major pharmaceutical companies for launch of the effective medications for infectious diseases propels the market's expansion.

Generation Insights

The second-generation segment dominated the cephalosporin drugs market with the largest share in 2023. The growth of the second-generation segment is attributed to its wider application in the medication of numerous infections. Second-generation cephalosporin is used in targeting the gram-positive and gram-negative bacteria. Second generation cover the broad range of bacterial infections such as impetigo, intraabdominal infection, joint infection, kidney infections, lyme disease, meningitis, otitis media, pelvic inflammatory disease, peritonitis, pneumonia, sepsis, septicemia, sinusitis, skin and structure infection, skin or soft tissue infection, strep throat, surgical prophylaxis, tonsillitis/pharyngitis, upper respiratory tract infection, urinary tract infection and wound infections. The second-generation cephalosporin drug includes cefaclor (Ceclor), cefuroxime (Ceftin), and ceprozil (Cefzil).

The third-generation segment is expected to witness a significant rate of growth during the forecast period. The third-generation cephalosporin is more effective in the treatment of gram-negative infections as compared to the other first and second-generation cephalosporin drug generation. The third-generation cephalosporin is used in the treatment of extremely harsh infections. Some of the expamples of third generation cephalosporin includes cefixime, ceftibuten, and cefpodoxime. 

Route of Administration Insights

The oral segment held the largest market share in the cephalosporin drugs market in 2023. The growth of the segment is increasing owing to the convenience to the patients. The oral segment includes the capsules, tablets, and oral suspensions which makes administration of medicines by the patients easier. Oral administration minimizes the healthcare costs related to the outpatient's care. Oral cephalosporin drug is used in the many severe bacterial infections such as urinary tract infections, respiratory tract infections, skin and soft tissue infections. The easy availability of the bacterial infection oral drug with enhanced treatment efficiency and ease in administration is observed to further promote the expansion of the market.

The injection segment is expected to grow at a significant rate in the cephalosporin drugs market during the forecast period. The administration of therapeutics via injections has become popular in recent years due to its effective and faster delivery of drug directly to the bloodstream. The injection cephalosporin drug is administered by injection for the critically infected patients in the hospital and in healthcare facilities. The segment includes intramuscular (IM) injections, and intravenous (IV) to fight against the various infectious diseases.  

Application Insights

The skin infection segment held the largest share of the cephalosporin drugs market in 2023. The growth of the segment is attributed to the rising skin infections in the people due to the bacterial infections and environmental pollution that drives the demand for the cephalosporin drugs in the skin infections. The abscesses, cellulitis, and impetigo, are some of the skin infections that are drives the demand for the cephalosprin drugs market. The higher demand for the cephalosprin drugs in the skin infections due to its antibacterial properties which reduces the infections causing agents, and promoted faster healing, and prevents the spread of infections. The rising environmental pollution is also one of the major factor for rise in the skin infections.

Respiratory tract infection segment is expected the signifiant growth in the market during the forecast period. The growth of the segment is rising owing to the geriatric population and environmental pollution causing the increased rate of respiratory infection among the people. Cephalosporin drug is used in the various type of infection and works in the large number of bacterial pathogens which are causing these type of dieases. Cephalosporin drugs is used for the faster recovery and fight against the respiratory infections.

Cephalosporin Drugs Market Recent Developments

• In April 2024, Zevtera (ceftobiprole medocaril sodium for injection) by the Basilea Pharmaceutical International Ltd. got the approval by the U.S. Food and Drug Administration (FDA) for the treatment of the serious bacterial infections in the pediatrics, and adults.
• In April 2024, the Mumbai-based Lupin, the pharmaceutical company granted the approval from the US Food and Drug Administration (USFDA) for launching the Mirabegron extended-release tablets (25 mg) in the United States market. The used of the Mirabegron extended tablets are for the treatment of bladder problems including the overactive bladder.
• In April 2024, Lupin a global major pharma company launched the generic version of Oracea (Doxycycline Capsules, 40 mg), after approval by the United States Food and Drug Administration (U.S. FDA) in the U.S. market.

Cephalosporin Drugs Market Companies

• Allergan Plc.
• Bristol-Myers Squibb Company
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline plc
• Lupin Limited
• Merck & Co. Inc.
• Novartis International AG (Sandoz)
• Pfizer Inc.
• Sanofi S.A.
• Teva Pharmaceutical Industries Ltd.
• Abbott Laboratories
• Sun Pharmaceutical Industries Limited

Segments Covered in the Report

By Generation

• First Generation
• Second Generation
• Third Generation
• Fourth Generation
• Fifth Generation

By Routes of Administration

• Oral
• Injection

By Application

• Skin Infection
• Respiratory Tract
• Ear Infection
• Urinary Tract Infection
• Sexually Transmitted Infection

By Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa